Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Regeneron Pharmaceuticals by 2.1%, now holding 710,335 shares worth approximately $450.5 million.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, significantly exceeding the consensus estimate of $8.43 and marking a 3.6% revenue increase year-over-year.
• The company declared a quarterly dividend of $0.88 per share, with an annualized yield of 0.6%, payable on September 3rd to shareholders on record by August 18th.

Charles Schwab Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 710,335 shares of the biopharmaceutical company's stock after acquiring an additional 14,536 shares during the period. Charles Schwab Investment Management Inc. owned 0.65% of Regeneron Pharmaceuticals worth $450,516,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Tompkins Financial Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Finally, Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $32,000. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on REGN. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective on the stock. in a report on Friday, August 1st. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective on the stock. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Bank of America cut their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Finally, JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $841.30.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ REGN traded up $3.20 during midday trading on Friday, reaching $563.00. 1,024,297 shares of the company's stock traded hands, compared to its average volume of 969,491. The company has a market cap of $60.78 billion, a price-to-earnings ratio of 14.19, a P/E/G ratio of 1.91 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a quick ratio of 4.73, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The stock's 50 day simple moving average is $536.80 and its 200-day simple moving average is $599.19.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.56 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.